Flare Therapeutics to Present New Translational Data in Support of Clinical Candidate FX-909’s Phase 1 Development at SITC 2023 Annual Meeting

Asher Bio Presents Promising New Preclinical Data for Cis-targeted Cancer Immunotherapy AB821 at SITC Annual Meeting

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society of Immunotherapy of Cancer

Rapport Therapeutics Appoints Chief Financial Officer

Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer